Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Greggs

(Sharecast News) - Analysts at Berenberg lowered their target price on fast-food bakery giant Greggs from 3,250.0p to 3,040.0p on Thursday, noting that like-for-like volatility had continued. Berenberg said that recent high temperatures across the UK had resulted in a deceleration in Greggs' like-for-like sales growth and a 5% downgrade to consensus expectations for FY25 adjusted operating profits.

Greggs reported 2.6% year-on-year like-for-like sales growth in H125, implying a roughly 1.3% deceleration relative to the first 20 weeks of FY25, something it attributed to worsening footfall trends stemming from warm weather.

Greggs now expects to see "a modest reduction" in adjusted operating profits in FY25, resulting in a roughly 5% downgrade to Visible Alpha consensus.

The German bank, which reiterated its 'buy' rating on the stock, said it continues to think Greggs' broader equity story "remains intact" despite the continuation of volatile trading conditions.

"We now project group lfl sales growth of 2% yoy in FY 2025E, down by 1ppt versus our prior forecast. This has resulted in a 6% downgrade to our adjusted operating profit forecast in FY 2025E given the impact of operating leverage," said Berenberg. "Our revised lfl forecast implies continued demand softness across July and August at levels similar to what is implied in June trading."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.